20 articles
END-seq reveals ALT-positive cancer telomeres share canonical 5′ ATC termini with normal cells, but harbor uniquely abundant single-stranded DNA regions.
Study of 183 brain tumor samples reveals distinct telomere maintenance patterns that could guide personalized cancer therapy.
A pyruvate metabolism enzyme suppresses leucine catabolism to keep mTOR active in liver cancer — and blocking it shrinks tumors in vivo.
Activated T cells release vesicles carrying genomic DNA that reprogram recipient cells to display tumor antigens more effectively.
New research shows how activating PKM2 enzyme enhances CD8 T cell function and improves anti-PD1 cancer therapy effectiveness.
Scientists discover how to reprogram cancer cells into harmless, non-dividing cells by targeting a nuclear enzyme pathway.
Scientists discover that maintaining proteostasis in tumor-infiltrating lymphocytes prevents exhaustion and boosts immunotherapy outcomes.
Scientists discover KLHL6 protein prevents immune cell dysfunction in tumors, offering new target for cancer immunotherapy.
Scientists identify a mitochondria-proteasome-haem pathway that silences immune cells — and show bortezomib can fix it in CAR-T therapy.
Study maps hepatitis B virus DNA integration sites in liver cancer, revealing distinct patterns that predict patient outcomes.
Scientists discover two new histone modifications that create a self-reinforcing cycle promoting breast cancer progression.
New study reveals how cancer cells reprogram bone immune cells to fuel metastasis, offering potential therapeutic targets.
New research reveals how progenitor cells drive the transition from benign to malignant cancer, offering potential intervention targets.
Novel treatment triggers ferroptosis in cancer cells while activating immune responses that further enhance cancer cell death.
A 73-patient study finds PD-L1 expression and TERT mutations identify high-grade thyroid cancers most likely to benefit from checkpoint inhibitor therapy.
A CRISPR screen reveals STK40 suppresses anti-tumor immunity in liver cancer — blocking it supercharges immunotherapy response.
Scientists discover that enhancing protein cleanup in immune cells prevents exhaustion and dramatically improves cancer immunity.
A landmark Cell study reveals cells transfer cytoplasmic DNA fragments to neighbors via nanotubes, stably reshaping recipient genomes.
New research reveals how tumors sabotage T cell metabolism by transferring dysfunctional mitochondria, offering fresh immunotherapy targets.
A newly identified lipid mediator may explain why immune cells fail to fight MASH-driven liver cancer, opening therapeutic targets.
